This is a University of Cincinnati research study to understand how effective and safe the study drug, currently approved for adults, is in children and teens with bipolar disorder with a current major depressive episode (MDE).
Children and teens 10 to 17 years old who have been diagnosed with bipolar I or II disorder and are currently experiencing an MDE may be eligible to participate.
The study involves up to 9 visits at the study center over 2 months. Here are some of the things that will happen in this study.
To find out the best way of treating children and teens with bipolar disorder, we need to compare different treatments. People are placed into groups, and each group is given a different study treatment. Each participant is put into a group by chance (this is called randomization). Participants in this study have a 1 in 2 chance of being randomly assigned (like flipping a coin) to receive the placebo or study drug.
If your child is taking certain medications not allowed in this study, you will be asked to discontinue those little by little during the screening period, under the supervision of the study doctor. Your child will not be allowed to take any other medications during the time they are in the study unless these are approved by the study doctor.
Your child will:
You, as the parent or guardian, will be given a supply of study drug for your child to take once each evening, under your supervision. The study team will advise you and your child about how best to take the study drug.
You and your child will be given a consent form that thoroughly explains all the details of the study. A member of the study staff will review the consent form with you and will be sure that all your questions are answered prior to the start of the study.
Participants may or may not benefit from taking part in this study. If your child is receiving the study drug, it is hoped that it will be of medical benefit to them, but this cannot be guaranteed. Information from this study may help researchers understand major depressive episodes associated with bipolar disorder with an MDE and develop new tests or medications to help other young people with this condition in the future.
We will discuss possible risks or discomforts with you and your child prior to the start of the study.
Participants may be compensated for study time and travel.
Maria Mastroianni
mastromi@ucmail.uc.edu
513-558-8950
University of Cincinnati
Psychiatry and Behavioral Neuroscience